Table 3 Univariate and multivariate analysis for survival outcomes after recurrence

FIGO stage

 I

ref

 II

1.736 [0.498–6.048]

0.387

 III

1.271 [0.678–2.385]

0.454

 IV

1.767 [0.845–3.691]

0.130

Histology

 Endometrioid G1/G2

ref

 Endometrioid G3

1.151 [0.550–2.408]

0.708

 Serous

0.906 [0.314–2.612]

0.885

 Other

1.792 [0.791–4.055]

0.162

Initial treatment

 ATH + BSO

ref

 ATH + BSO + PLA biopsy

0.678 [0.280–1.638]

0.388

 ATH + BSO + PLA

0.659 [0.327–1.329]

0.244

 ATH + BSO + PLA + PAN

0.596 [0.275–1.288]

0.188

 NAC + ATH + BSO

0.830 [0.235–2.928]

0.772

Time to recurrence

0.999 [0.0998–1.000]

0.008

Recurrence site

 Local

ref

ref

 Pelvic and para-aortic LN

5.836 [2.143–15.892]

0.001

5.311 [1.866–15.114]

 Peritoneal dissemination

3.088 [1.061–8.984]

0.039

2.699 [0.910–8.004]

 Distant metastasis

4.100 [1.6961–9.911]

0.002

3.876 [1.542–9.743]

Diagnosis method at recurrence

 Outpatient exam

ref

 Symptom

1.042 [0.429–2.529]

0.928

 Tumor marker

1.830 [0.797–4.353]

0.172

 Imaging analysis

1.385 [0.640–2.999]

0.409